Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer

NCT00567554 is registered in ClinicalTrials.gov with GBG Forschungs GmbH as lead sponsor.

NCT NCT00567554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00567554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer
Lead sponsor
GBG Forschungs GmbH
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2007
Completion date
October 31, 2015
Enrollment
2,600 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer